# A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma

Source: https://onco.cc/trials/nct05755113/  
OnCo record `nct05755113` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tigilanol Tiglate in sarcomas, run by QBiotics Group Limited, now recruiting.

## Summary

A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT05755113 by QBiotics Group Limited, with 40 participants planned, started 2023-04-13 and due to reach its primary completion in 2027-01. Interventions recorded: Tigilanol Tiglate.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05755113
- Phase: 2
- Setting: A Phase IIa Open Label Study Evaluating the Preliminary Efficacy of Intratumoural Tigilanol Tiglate in Advanced and/or Metastatic Soft Tissue Sarcoma of the Extremities and Body Wall.
- Sponsor: QBiotics Group Limited
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT05755113: https://clinicaltrials.gov/study/NCT05755113

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- companies: [QBiotics](https://onco.cc/companies/qbiotics/)

---
JSON: https://onco.cc/api/v1/entities/nct05755113.json